• Notorious RSV

  • Jul 2 2024
  • Duración: 17 m
  • Podcast

Notorious RSV

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Last year, the healthcare system faced a surge of COVID, influenza, and RSV cases, filling hospitals with children in critical condition. Despite the introduction of a promising new RSV treatment, nirsevimab, its rollout was hampered by supply shortages and logistical challenges. Daniel Dodson, MD, MS, a pediatric infectious disease specialist, explained that the limited supply required careful allocation to high-risk infants, leading to difficult decisions and impassioned pleas from caregivers.

    Resources:
    • Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals - Pediatric Pandemic Network
    • Nirsevimab Frequently Asked Questions - American Academy of Pediatrics
    • Nirsevimab for Prevention of RSV in Healthy Late -Preterm and Term Infants - The New England Journal of Medicine
    • Immunizations to Protect Infants - CDC
    Más Menos
Enfermedades Físicas Hygiene & Healthy Living Historia Ciencias Sociales Éxito Personal
Más Menos

Lo que los oyentes dicen sobre Notorious RSV

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles